Polymyxins for the treatment of lower respiratory tract infections; lessons learned from the integration of clinical pharmacokinetic studies and clinical outcomes
The global rise in nosocomial pneumonia caused by multidrug-resistant (MDR) Gram-negative pathogens and increasingly limited antibiotic treatment options are growing threats to modern medicine. As a result, older antibiotics like polymyxins are being used as drugs of last resort for MDR nosocomial pneumonia. Polymyxins are bactericidal against most aerobic Gram-negative bacilli, but the sub-therapeutic concentrations achieved at infection sites following high-dose intravenous administration make…